Bavituximab to Star in Phase II Hepatitis C Trial | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Two Supplements May Strengthen Hep C Antiviral Treatment

Back to News Homepage
Next

Better Drugs, Hep C Testing and Baby Boomers

Bavituximab to Star in Phase II Hepatitis C Trial

The Editors at Hepatitis Central
January 20, 2011

Print this page

Peregrine Pharmaceuticals, Inc. has started a Phase II clinical trial to determine if bavituximab plus ribavirin elicits an early virologic response in people with previously untreated genotype-1 Hepatitis C.

Peregrine Initiates Randomized Phase II Trial of Bavituximab in Chronic Hepatitis C

Open-Label Trial Evaluating 12 Weeks of Therapy With Novel Targeted Antibody Bavituximab in Combination With Ribavirin Versus Standard of Care

TUSTIN, CA–(Marketwire – January 10, 2011) – Peregrine Pharmaceuticals, Inc.

(NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it has initiated a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection. This open-label trial will determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with Peregrine’s bavituximab, a phosphatidylserine (PS)-targeting monoclonal antibody with immune-modulating potential, in combination with the antiviral drug ribavirin versus standard of care, pegylated interferon alpha 2a and ribavirin. Peregrine expects to complete enrollment shortly in an ongoing Phase Ib HCV trial and report data by mid-year.

Continue reading this entire article:
http://www.marketwire.com/press-release/Peregrine-Initiates-Randomized-Phase-II-Trial-of-Bavituximab-in-Chronic-Hepatitis-C-NASDAQ-PPHM-1377628.htm

No Comments - be the first!
Share
Share
Previous

Two Supplements May Strengthen Hep C Antiviral Treatment

Back to News Homepage
Next

Better Drugs, Hep C Testing and Baby Boomers

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.